VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 330 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2017. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,132,000 | +69.7% | 134,784 | +16.2% | 2.87% | +48.4% |
| Q1 2018 | $1,846,000 | -30.4% | 115,970 | -9.1% | 1.93% | -28.6% |
| Q4 2017 | $2,651,000 | +139.3% | 127,567 | +65.0% | 2.71% | +99.8% |
| Q3 2017 | $1,108,000 | -17.1% | 77,311 | 0.0% | 1.36% | -33.0% |
| Q2 2017 | $1,337,000 | +56.7% | 77,311 | 0.0% | 2.02% | +71.4% |
| Q1 2017 | $853,000 | +66.9% | 77,311 | +119.9% | 1.18% | +65.4% |
| Q4 2016 | $511,000 | -15.7% | 35,165 | +42.6% | 0.71% | -29.2% |
| Q3 2016 | $606,000 | +195.6% | 24,665 | +142.6% | 1.01% | +193.3% |
| Q2 2016 | $205,000 | -58.3% | 10,165 | -45.7% | 0.34% | -63.5% |
| Q1 2016 | $492,000 | +24.2% | 18,715 | +379.9% | 0.94% | +77.6% |
| Q4 2015 | $396,000 | – | 3,900 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |